IMMUNITYBIO, INC. Marketable Securities (Non-Current)
IMMUNITYBIO, INC. (IBRX) had Marketable Securities (Non-Current) of $0 as of 2024-12-31, per its 10-K filed 2025-03-03.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:MarketableSecuritiesNoncurrent · last filed 2025-03-03
- 2024-12-31: Marketable Securities, Noncurrent $0.00.
- 2024-09-30: Marketable Securities, Noncurrent $0.00.
- 2024-06-30: Marketable Securities, Noncurrent $0.00.
- 2024-03-31: Marketable Securities, Noncurrent $0.00.
| Period end | Marketable Securities, Noncurrent |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-03 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-12 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 |
| 2023-12-31 | $891.00K 10-K · filed 2025-03-03 |
| 2023-09-30 | $817.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $841.00K 10-Q · filed 2023-08-08 |
| 2023-03-31 | $820.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $840.00K 10-K · filed 2024-03-19 |
| 2022-09-30 | $811.00K 10-Q · filed 2022-11-09 |
| 2022-06-30 | $914.00K 10-Q · filed 2022-08-08 |
| 2022-03-31 | $865.00K 10-Q · filed 2022-05-10 |
| 2021-12-31 | $822.00K 10-K · filed 2023-03-01 |
| 2021-09-30 | $802.00K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $822.00K 10-Q · filed 2021-08-12 |
| 2021-03-31 | $1.00M 10-Q · filed 2021-05-14 |
| 2020-12-31 | $950.00K 10-K · filed 2022-03-01 |
| 2019-12-31 | $2.16M 8-K/A · filed 2021-04-22 |
| 2017-12-31 | $29.60M 10-K · filed 2018-03-12 |
| 2017-09-30 | $34.20M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $47.05M 10-Q · filed 2017-08-07 |
| 2017-03-31 | $71.49M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $87.57M 10-K · filed 2018-03-12 |
| 2016-09-30 | $94.66M 10-Q · filed 2016-11-10 |
| 2016-06-30 | $107.93M 10-Q · filed 2016-08-15 |
| 2016-03-31 | $116.20M 10-Q · filed 2016-05-16 |
| 2015-12-31 | $55.13M 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |